Condition
Moderate to Severe Chronic Obstructive Pulmonary Disease
Total Trials
2
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
Treatment Research
4 treatments under study, led by Tilrekimig
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Phase 2/3 (1)
Phase 3 (1)
Trial Status
Recruiting1
Not Yet Recruiting1
Clinical Trials (2)
Showing 2 of 2 trials
NCT07363694Phase 2/3RecruitingPrimary
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT07839884Phase 3Not Yet RecruitingPrimary
A Continuation Study of Tilrekimig in Adults With Moderate-to-Severe Long-Term Breathing Difficulty, Known by the Medical Term of Chronic Obstructive Pulmonary Disease (COPD) to Learn About This Medicine When Used for a Long Period of Time
Showing all 2 trials
Research Network
Common Treatments
- Tilrekimig1
- Pf07275315 Dose 11
- Pf07275315dose 21
- Pf07275315dose 31
Active Sponsors
- Pfizer2
- Pfizer Inc.1
Related Conditions
- Moderatetosevere Chronic Obstructive Pulmonary Disease Copd1